Astec LifeSciences Limited — Updates, 27-01-2025: Press Release

Astec LifeSciences Limited reported a significant increase in consolidated total income for Q3 FY25, reaching ₹ 95.8 Crore, up 85.2% from ₹ 51.7 Crore in Q3 FY24. The EBITDA losses narrowed to ₹ 3.8 Crore from ₹ 17.4 Crore in the same period last year, marking a sequential improvement from ₹ 17.7 Crore in Q2 FY25. For the first nine months of FY25, total income was ₹ 266.6 Crore compared to ₹ 308.0 Crore in the previous year, with EBITDA losses worsening to ₹ 66.9 Crore from ₹ 15.0 Crore in 9M FY24. The Chairman, Mr. N B Godrej, indicated that the company's performance is showing signs of gradual improvement, driven largely by increased volumes in the Contract Development and Manufacturing Organization (CDMO) sector, despite ongoing challenges with lower realizations in key enterprise products. The positive trend warrants a closer watch as the company aims for better performance in the upcoming quarters.